QHMAC meeting outcomes-February 2014 - CATAG



MemorandumTo:HHS CEOsDirectors of Medical ServicesDirectors of PharmacyChairs, Medicines Advisory CommitteesCopies to:QHPIMS-Support UnitDispensary ManagersQHMAC MembersCentral Pharmacy (Graham Cook, Robin Lee, Nicole Zischke, Sam Webb)CIRCS (Maree Bransdon)From:Stephanie Boydell, Acting Executive Secretary Queensland Health Medicines Advisory CommitteeContact No:3131 6516Fax No: 3131 6568Subject:Summary of changes to the Queensland Health List of Approved Medicines (LAM) as a result of the February 2014 Queensland Health Medicines Advisory Committee (QHMAC) meetingFile Ref:CASS/0009421402advAt the February 2014 meeting the Queensland Health Medicines Advisory Committee (QHMAC) recommended the following changes to the List of Approved Medicines (LAM). These have been approved by the Committee Sponsor, Chief Executive, Health Services Support Agency (HSSA) and will be effective from 1 April 2014 - or as otherwise stated in the attached. There are six editions of the LAM each year. These current changes will be included in the 1 April 2014 edition of the LAM which will be published on QHEPS at . Please distribute this document as deemed appropriate to relevant clinicians. For future reference, monthly Summary of Changes can be found under “QHMAC meeting outcomes” at Note: These amendments may also include a number of items which are planned for earlier inclusion in the LAM – such as medicines which are available under the Highly Specialised Drugs Program or for which QHMAC specifically endorsed an earlier inclusion date.SignedVicki Mackintosh(for) Stephanie BoydellActing Executive SecretaryQueensland Health Medicines Advisory Committee31 / 03 / 2014Item No.MedicineDecision & date effectiveRestriction14/001Meglumine diatrizoate with sodium diatrizoate Solution 66% - 10%, 100mL"Gastrografin"Amended1 June 14Use as a radiographic contrast medium for examination of the gastrointestinal tract 14/012Changes to efficient funding of chemotherapy (EFC)Deferred?14/011Changes to highly specialised drugs program (HSDP)Deferred?13/101ADalteparin sodium prefilled syringe, single dose subcutaneous injection 5,000 IU in 0.2mLDeferred[pending RBWH advice re any safety issues since changing to dalteparin for VTE prophylaxis.]14/007Fat emulsion - soya oil, MCT, Olive Oil, Fish Oil "SMOFlipid 20%" IV Infusion 20%, 100mLDeferred14/010Ivabradine tablet 5mg, 7.5mgDeferred13/103Omeprazole suspension 2mg per mL, 100mLDeferred 14/003Reactivated item - fondaparinux sodium injection PFS 2.5mg in 0.5mLDeferredReviewing Individual Patient Approval (IPA) guideline for use in VTE prophylaxis [Also see FONDAPARINUX – item 14/002 under “NOT ADDED” items].?13/105Sodium chloride 0.9% Prefilled syringe 10mL (BD Posiflush)Deferred14/008Vaccines for stem cell transplant recipientsDeferred14/005Aflibercept intravitreal injection 4mg in 0.1mLNot added14/002Fondaparinux sodium injection PFS 2.5mg in 0.5mLNot added Recommended a new IPA guideline be developed for use in HIT/TS14/006Nebivolol tablet 1.25mg, 5mg, 10mgNot added14/009Pazopanib tablet 200mg, 400mgNot addedNB - this recommendation was reconsidered at the March 2014 meeting13/094Cyclizine lactate 50mg in 1mLNot added13/102Amphotericin injection liposomal 50mgNoted14/004QHMAC annual report 2012-2013Noted7_Feb 14A & B(A) CATAG guiding principles for off-label-use (B) CATAG guiding principles for DTCs Noted ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download